Mongolia - MNT300 Million for FMD
As the spread of FMD still continued and the disease outbreak risk is still high, the Cabinet has decided to allocate MNT300 million for the purchase of 600,000 dozes of vaccine from Russia and for injection costs.
Page 20 of articles about vaccine
Sanitary Equilibrium: The role of PCV2 vaccines
The most common problems are due to interference with maternal antibodies and coincidence of vaccination with a recirculation of PRRS: viremic animals.
The effect of supplementing dry feed with a nutritional gel additive at the time of vaccination on nursery pig behaviour
A nutritional gel supplementation reduces the negative impact of vaccination on piglet behaviour.
Dynamics and longevity of maternally-acquired antibodies to Taenia solium in piglets born to naturally infected sows
The observed variations in the level of maternally-acquired Abs amongst piglets will pose a major challenge to the implementation of vaccination programmes against T. solium cysticercosis.
Day one Mycoplasma hyopneumoniae vaccination now possible with RespiSure-ONE®
Pork producers in US can now vaccinate for mycoplasmal pneumonia at day one.
Intervet/Schering-Plough animal health demonstrates efficacy of simultaneous use of circovirus and mycoplasma vaccines in swine
Simultaneous (mixed) use of existing swine vaccines against porcine circovirus 2 (PCV2) and Mycoplasma hyopneumoniae (M. hyo) from Intervet/Schering-Plough Animal Health in swine are as efficacious and safe as separate use of these vaccines.
IDRI And Merial Enter Into Research Collaboration
Global animal health company Merial Ltd. and non-profit biotechnology organization the Infectious Disease Research Institute (IDRI) today announce they have agreed to cooperate regarding the research and development of certain vaccines for animals.
Biolex and Merial Broaden Collaboration
Biolex Therapeutics, Inc and Merial Ltd today announced that they have entered into a new, broad-ranging research and development collaboration to produce innovative veterinary vaccines.
First PCV-2 / Mycoplasma hyopneumoniae vaccine combination registered in the European Union
The EU Commission has approved the simultaneous use of the pig vaccines Ingelvac CircoFLEX® and Ingelvac MycoFLEX® in the European Union. Boehringer Ingelheim will market this unique vaccine concept under the name FLEXcombo®.
Boehringer Ingelheim launches PCV2 vaccine in Russia
With the launch of Ingelvac CircoFLEX® by Boehringer Ingelheim on the Russian market, pig producers in Russia now have access to the world’s market leading vaccine against porcine Circovirus type 2 (PCV2).
Intervet/Schering-Plough Animal Health receives positive opinion in europe for simultaneous use of Porcilis® PRRS and Porcilis® M hyo vaccines in piglets
Intervet/Schering-Plough Animal Health, announces today that the Committee for Medicinal Products for Veterinary Use (CVMP) of the European Medicines Agency (EMA) concluded the referral procedure for PORCILIS® PRRS and for PORCILIS® M Hyo on simultaneous administration of these products in piglets
European Union - Commission clears acquisition of anial health assets of Pfizer by Eli Lilly&Co
The European Commission has granted clearance under the EU Merger Regulation to the acquisition of animal health assets of Pfizer by Eli Liily & Co, both of the USA.
In silico prediction and ex vivo evaluation of potential T-cell epitopes in glycoproteins 4 and 5 and nucleocapsid protein of genotype-I (European) of porcine reproductive and respiratory syndrome virus
Researchers of the CReSA have described for the first time antigenic sites of PRRSV that are recognized by T cells, using bioinformatics tools and later immunological analysis. All these information is relevant for the design of newer and better vaccines.
Intervet/Schering-Plough Animal Health opens state-of-the-art vaccine manufacturing facility at Biosciences Center Boxmeer
Intervet/Schering-Plough Animal Health announces that it will open today a state-of-the-art production center for veterinary vaccines against bacterial infections. The new facility is located at Biosciences Center Boxmeer, one of the world’s largest veterinary R&D and manufacturing facilities and a cornerstone of the company’s global vaccine R&D and production network.
MERIAL launches the first-ever trivalent vaccine against swine influenza to include the H1N2 subtype: GRIPOVAC®3
H1N2, H1N1 and H3N2 are the three influenza A virus subtypes of the Swine Influenza virus contained in GRIPOVAC®3, a new vaccine against swine influenza.
IDT Biologika: New swine flu vaccine protects against three virus subtypes
IDT Biologika has developed and is marketing the first swine influenza vaccine - Respiporc Flu3 - registered for protection against the three most clinically significant subtypes of the virus, H1N1, H3N2 and H1N2.